{
  "id": "1c4ffcbe09138d05",
  "title": "Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI\u2122 ( Ziftomenib ) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed / Refractory AML",
  "description": "20251208T160000Z",
  "content": "",
  "source": "manilatimes.net",
  "source_url": "https://www.manilatimes.net/2025/12/08/tmt-newswire/globenewswire/kura-oncology-and-kyowa-kirin-report-combination-data-for-komzifti-ziftomenib-with-venetoclax-and-azacitidine-in-newly-diagnosed-and-relapsedrefractory-aml/2239196",
  "published_at": "20251208T160000Z",
  "fetched_at": "2025-12-09T00:22:19.510482+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [],
  "location": "Philippines",
  "raw_data": {
    "url": "https://www.manilatimes.net/2025/12/08/tmt-newswire/globenewswire/kura-oncology-and-kyowa-kirin-report-combination-data-for-komzifti-ziftomenib-with-venetoclax-and-azacitidine-in-newly-diagnosed-and-relapsedrefractory-aml/2239196",
    "url_mobile": "https://www.manilatimes.net/2025/12/08/tmt-newswire/globenewswire/kura-oncology-and-kyowa-kirin-report-combination-data-for-komzifti-ziftomenib-with-venetoclax-and-azacitidine-in-newly-diagnosed-and-relapsedrefractory-aml/2239196/amp",
    "title": "Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI\u2122 ( Ziftomenib ) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed / Refractory AML",
    "seendate": "20251208T160000Z",
    "socialimage": "https://www.manilatimes.net/manilatimes/uploads/images/2025/12/08/859053.png",
    "domain": "manilatimes.net",
    "language": "English",
    "sourcecountry": "Philippines"
  }
}